The FDA’s big gamble on the new Alzheimer’s drug

+News

The FDA’s big gamble on the new Alzheimer’s drug

The conversation

The Conversation

Pills
Do the benefits of approving a drug before confirming it works outweigh the potential costs?
The Food and Drug Administration set off a firestorm of debate when it approved a new drug, aducanumab, for Alzheimer’s disease via an accelerated app